Cost-effectiveness of combining finerenone and sodium-glucose cotransporter 2 inhibitors with standard of care for patients with chronic kidney disease and type 2 diabetes in China

Objective To evaluate the cost-effectiveness of combining finerenone and Sodium-glucose cotransporter-2 inhibitors (SGLT2i) with standard care (SoC) for Chinese patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).Methods A validated Markov model (FINE-CKD) was employed to simulate h...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Zhengqiang Hu, Wei Jin, Shengying Lou, Lejun Zhang
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Taylor & Francis Group 2025-12-01
Ráidu:	Renal Failure
Fáttát:	Cost-effectiveness analysis chronic kidney disease type 2 diabetes finerenone sodium-glucose cotransporter 2 inhibitors
Liŋkkat:	https://www.tandfonline.com/doi/10.1080/0886022X.2025.2578413
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!